MWNA
AGIO icon

Marshall Wace North America’s Agios Pharmaceuticals AGIO Stock Holding History

Marshall Wace North America’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-27,958
Closed -$979K – 1278
2020
Q3 		$979K Buy
27,958
+7,252
+35% +$318K 0.01% 810
2020
Q2 		$1.11M Buy
+20,706
New +$959K 0.01% 731
2019
Q4 		– Sell
-419,574
Closed -$13.6M – 1261
2019
Q3 		$13.6M Buy
419,574
+316,183
+306% +$13.1M 0.08% 212
2019
Q2 		$5.16M Buy
+103,391
New +$5.53M 0.03% 355
2019
Q1 		– Sell
-6,684
Closed -$308K – 1523
2018
Q4 		$308K Sell
6,684
-204,385
-97% -$12.6M ﹤0.01% 883
2018
Q3 		$16.3M Sell
211,069
-84,689
-29% -$6.81M 0.11% 157
2018
Q2 		$24.9M Sell
295,758
-43,036
-13% -$3.75M 0.14% 173
2018
Q1 		$27.7M Buy
338,794
+103,969
+44% +$8.04M 0.14% 167
2017
Q4 		$13.4M Sell
234,825
-3,556
-1% -$224K 0.07% 313
2017
Q3 		$16M Buy
+238,381
New +$14.3M 0.1% 259
2013
Q4 		$361K Sell
15,054
-2,657
-15% -$60.6K 0.01% 568
2013
Q3 		$495K Buy
+17,711
New +$489K 0.02% 447

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace North America's AGIO Position: Q4 2020 in Review

Marshall Wace North America sold out of Agios Pharmaceuticals (AGIO) in Q4 2020, closing a stake of 27,958 shares — an estimated $979K sold.

Marshall Wace North America first reported a position in AGIO in Q3 2013 and held it in 12 quarters. The position peaked at $27.7M in Q1 2018. 200 funds tracked by Wall St. Rank hold AGIO as of Q4 2020.

  • Marshall Wace North America reported no remaining Agios Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 27,958 Agios Pharmaceuticals shares in Q4 2020, an estimated $979K.
  • Marshall Wace North America first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 12 quarters.
  • Marshall Wace North America's Agios Pharmaceuticals position peaked at $27.7M in Q1 2018.
  • 200 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.